Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Generic Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:DEPO
- CUSIP: 24990810
- Web: www.depomedinc.com
Capitalization:- Market Cap: $374.15 million
- Outstanding Shares: 62,988,000
Average Prices:- 50 Day Moving Avg: $6.69
- 200 Day Moving Avg: $10.50
- 52 Week Range: $5.81 - $27.02
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -11.38
- P/E Growth: 0.49
Sales & Book Value:- Annual Revenue: $425.34 million
- Price / Sales: 0.88
- Book Value: $3.36 per share
- Price / Book: 1.76
Profitability:- EBIDTA: $112.64 million
- Net Margins: -26.02%
- Return on Equity: -45.03%
- Return on Assets: -9.34%
Debt:- Debt-to-Equity Ratio: 2.71%
- Current Ratio: 0.79%
- Quick Ratio: 0.75%
Misc:- Average Volume: 1.62 million shs.
- Beta: 1.23
- Short Ratio: 8.72
Frequently Asked Questions for Depomed (NASDAQ:DEPO)
What is Depomed's stock symbol?
Depomed trades on the NASDAQ under the ticker symbol "DEPO."
How were Depomed's earnings last quarter?
Depomed, Inc. (NASDAQ:DEPO) issued its earnings results on Monday, August, 7th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of $0.09 by $0.52. The company had revenue of $100 million for the quarter, compared to analysts' expectations of $100.40 million. Depomed had a negative return on equity of 45.03% and a negative net margin of 26.02%. Depomed's revenue for the quarter was down 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.27 earnings per share. View Depomed's Earnings History.
When will Depomed make its next earnings announcement?
Where is Depomed's stock going? Where will Depomed's stock price be in 2017?
9 analysts have issued 12 month price targets for Depomed's stock. Their forecasts range from $5.00 to $24.00. On average, they expect Depomed's share price to reach $13.22 in the next year. View Analyst Ratings for Depomed.
What are analysts saying about Depomed stock?
Here are some recent quotes from research analysts about Depomed stock:
- 1. Cantor Fitzgerald analysts commented, "After the March 28 close, DEPO announced an agreement with Starboard that replaces CEO Jim Schoeneck as well as two incumbent board members. Guidance for 1Q17 revenue was also released, $95-100M vs. FactSet estimate." (3/29/2017)
- 2. Janney Montgomery Scott analysts commented, "Recent developments in the 2013 patent litigation brought by DEPO against Purdue have resulted in DEPO filing an amended complaint claiming Purdue willfully violated its patents. The dispute pertains to DEPO's claim that Purdue's abuse-deterrent formulation of OxyContin, which was approved by the FDA on April 5, 2010 and subsequently commercialized, relies on inventions protected by patents for DEPO's Acuform?? drug delivery technology. With a potential royalty on cumulative net sales of $10 billion at stake, we have previously estimated, and continue to believe, a damage award of $200 million or more is possible, with little to no downside risk to DEPO in the process. We note our prior estimate did not contemplate an enhanced damage award that may result in a treble (3x) damages if DEPO prevails." (2/27/2017)
Who are some of Depomed's key competitors?
Some companies that are related to Depomed include U.S. Physical Therapy (USPH), AtriCure (ATRC), Revance Therapeutics (RVNC), Audentes Therapeutics (BOLD), CryoLife (CRY), Ignyta (RXDX), Alder BioPharmaceuticals (ALDR), LeMaitre Vascular (LMAT), AnaptysBio (ANAB), G1 THERAPEUTICS (GTHX), Civitas Solutions (CIVI), Aclaris Therapeutics (ACRS), Paratek Pharmaceuticals (PRTK), Achaogen (AKAO), Seres Therapeutics (MCRB), Coherus BioSciences (CHRS), WAVE Life Sciences (WVE) and Abeona Therapeutics (ABEO).
Who are Depomed's key executives?
Depomed's management team includes the folowing people:
- James P. Fogarty CPA, Chairman of the Board
- Arthur J. Higgins, President, Chief Executive Officer, Director
- August J. Moretti, Chief Financial Officer, Senior Vice President
- Matthew M. Gosling, Senior Vice President, General Counsel
- Sharon D. Larkin, Senior Vice President - Human Resources and Administration.
- Gerd G. Kochendoerfer, Senior Vice President, Technical Development & Quality
- Karen A. Dawes, Independent Director
- Louis J. Lavigne Jr., Independent Director
- William T. McKee CPA, Independent Director
- Gavin T. Molinelli, Independent Director
Who owns Depomed stock?
Depomed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
STARBOARD VALUE LP
(8.70%), Vanguard Group Inc. (6.95%), State Street Corp (3.71%), Dimensional Fund Advisors LP (3.70%), Oak Ridge Investments LLC (3.69%) and Deltec Asset Management LLC (1.64%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti and Thadd M Vargas. View Institutional Ownership Trends for Depomed.
Who sold Depomed stock? Who is selling Depomed stock?
Depomed's stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Vanguard Group Inc., Public Employees Retirement Association of Colorado, Capital Fund Management S.A., Cornerstone Capital Management Holdings LLC., Hussman Strategic Advisors Inc., OxFORD Asset Management LLP and Oak Ridge Investments LLC. View Insider Buying and Selling for Depomed.
Who bought Depomed stock? Who is buying Depomed stock?
Depomed's stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, ING Groep NV, State of Wisconsin Investment Board, Clark Estates Inc. NY, Marshall Wace North America L.P., Sivik Global Healthcare LLC, Systematic Financial Management LP and FMR LLC. View Insider Buying and Selling for Depomed.
How do I buy Depomed stock?
Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Depomed's stock price today?
One share of Depomed stock can currently be purchased for approximately $5.92.
MarketBeat Community Rating for Depomed (NASDAQ DEPO)MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Depomed (NASDAQ:DEPO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 5 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.22) |
| Consensus Price Target: | $13.22 (123.35% upside) |
Analysts' Ratings History for Depomed (NASDAQ:DEPO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/10/2017 | Piper Jaffray Companies | Reiterated Rating | Hold | $9.00 | High |  |
| 8/8/2017 | Morgan Stanley | Downgrade | Equal Weight -> Underweight | $12.00 -> $5.00 | High | |
| 8/8/2017 | Royal Bank Of Canada | Lower Price Target | Sector Perform -> Sector Perform | $13.00 -> $10.00 | High | |
| 8/8/2017 | Janney Montgomery Scott | Downgrade | Buy -> Neutral | $18.00 -> $8.00 | High | |
| 5/25/2017 | Mizuho | Lower Price Target | Neutral | $13.00 -> $11.00 | Medium | |
| 5/15/2017 | Cantor Fitzgerald | Set Price Target | Hold | $14.00 | Medium | |
| 3/30/2017 | JMP Securities | Reiterated Rating | Outperform | $30.00 -> $16.00 | High | |
| 2/18/2017 | Roth Capital | Set Price Target | Buy | $24.00 | N/A | |
| 11/8/2016 | Leerink Swann | Set Price Target | Buy | $22.00 | N/A | |
| 3/24/2016 | Northland Securities | Initiated Coverage | Outperform | $22.00 | N/A | |
| 2/24/2016 | WallachBeth Capital | Lower Price Target | Buy | $33.00 -> $27.00 | N/A | |
(Data available from 9/22/2015 forward)
Earnings History for Depomed (NASDAQ:DEPO)Earnings History by Quarter for Depomed (NASDAQ DEPO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | $0.12 | | | | | N/A | |
| 8/7/2017 | Q2 2017 | $0.09 | ($0.43) | $100.40 million | $100.00 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.25) | ($0.43) | $99.48 million | $95.00 million | View | Listen | |
| 2/21/2017 | Q4 2016 | $0.36 | $0.48 | $123.00 million | $123.90 million | View | Listen | |
| 11/7/2016 | Q3 | $0.35 | $0.28 | $127.22 million | $111.00 million | View | Listen | |
| 8/3/2016 | Q2 | $0.26 | $0.27 | $118.20 million | $116.70 million | View | Listen | |
| 5/5/2016 | Q1 | $0.17 | $0.12 | $106.88 million | $104.60 million | View | Listen | |
| 2/22/2016 | Q415 | $0.29 | $0.16 | $110.19 million | $111.20 million | View | Listen | |
| 11/9/2015 | Q3 | $0.19 | $0.33 | $101.64 million | $105.00 million | View | Listen | |
| 7/29/2015 | Q215 | ($0.45) | $0.27 | $88.33 million | $94.30 million | View | Listen | |
| 5/11/2015 | Q115 | $0.07 | ($0.13) | $33.80 million | $31.70 million | View | Listen | |
| 2/23/2015 | Q414 | $0.07 | $0.21 | $44.66 million | $33.90 million | View | Listen | |
| 11/5/2014 | Q314 | ($0.04) | ($0.01) | $41.50 million | $51.49 million | View | Listen | |
| 8/6/2014 | Q214 | ($0.06) | ($0.03) | $38.03 million | $67.70 million | View | Listen | |
| 5/8/2014 | Q114 | $0.11 | ($0.04) | $53.57 million | $76.50 million | View | Listen | |
| 3/12/2014 | Q413 | ($0.21) | $0.72 | $19.06 million | $40.60 million | View | Listen | |
| 11/5/2013 | Q313 | $0.07 | $0.11 | $35.55 million | $37.50 million | View | Listen | |
| 8/7/2013 | Q2 2013 | ($0.05) | $0.01 | $29.87 million | $30.00 million | View | Listen | |
| 5/8/2013 | Q1 2013 | ($0.06) | ($0.10) | $28.93 million | $26.20 million | View | Listen | |
| 2/20/2013 | Q4 2012 | ($0.11) | ($0.07) | $26.48 million | $26.60 million | View | Listen | |
| 11/5/2012 | Q312 | ($0.11) | ($0.03) | $28.06 million | $33.30 million | View | N/A | |
| 8/2/2012 | | ($0.22) | ($0.28) | | | View | N/A | |
| 5/8/2012 | | ($0.24) | ($0.16) | | | View | N/A | |
| 3/8/2012 | | ($0.31) | ($0.25) | | | View | N/A | |
| 11/1/2011 | | ($0.23) | ($0.15) | | | View | N/A | |
| 8/1/2011 | | ($0.05) | ($0.11) | | | View | N/A | |
| 5/5/2011 | | $1.05 | $1.77 | | | View | N/A | |
| 3/3/2011 | | $0.06 | $0.03 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Depomed (NASDAQ:DEPO)2017 EPS Consensus Estimate: ($0.20)
2018 EPS Consensus Estimate: $0.38
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.25) | ($0.20) | ($0.23) |
| Q2 2017 | 2 | ($0.32) | ($0.04) | ($0.18) |
| Q3 2017 | 2 | ($0.05) | $0.04 | ($0.01) |
| Q4 2017 | 2 | $0.05 | $0.38 | $0.22 |
| Q1 2018 | 1 | $0.03 | $0.03 | $0.03 |
| Q2 2018 | 1 | $0.09 | $0.09 | $0.09 |
| Q3 2018 | 1 | $0.12 | $0.12 | $0.12 |
| Q4 2018 | 1 | $0.14 | $0.14 | $0.14 |
(Data provided by Zacks Investment Research)
Dividend History for Depomed (NASDAQ:DEPO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Depomed (NASDAQ:DEPO)Insider Ownership Percentage: 2.59%
Institutional Ownership Percentage: 91.25%
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/12/2017 | Arthur J Higgins | Insider | Buy | 15,000 | $9.92 | $148,800.00 | |
| 11/14/2016 | August J Moretti | CFO | Sell | 5,000 | $20.84 | $104,200.00 | |
| 9/21/2016 | Thadd M Vargas | VP | Sell | 11,250 | $25.00 | $281,250.00 | |
| 8/10/2016 | August J. Moretti | CFO | Sell | 5,000 | $21.40 | $107,000.00 | |
| 8/10/2016 | Thadd M Vargas | VP | Sell | 26,290 | $20.92 | $549,986.80 | |
| 5/23/2016 | Thadd M Vargas | VP | Sell | 15,000 | $20.00 | $300,000.00 | |
| 5/10/2016 | Thadd M Vargas | VP | Sell | 15,000 | $17.64 | $264,600.00 | |
| 5/9/2016 | August J Moretti | CFO | Sell | 5,000 | $18.00 | $90,000.00 | |
| 3/11/2016 | Thadd M Vargas | VP | Sell | 23,000 | $16.00 | $368,000.00 | |
| 12/3/2015 | August J. Moretti | CFO | Sell | 15,000 | $18.11 | $271,650.00 | |
| 6/12/2015 | Thadd M Vargas | VP | Sell | 5,000 | $20.70 | $103,500.00 | |
| 12/2/2014 | August J Moretti | CFO | Sell | 5,339 | $15.85 | $84,623.15 | |
| 12/2/2014 | James A Schoeneck | CEO | Sell | 36,727 | $15.85 | $582,122.95 | |
| 12/2/2014 | Thadd M Vargas | VP | Sell | 8,247 | $15.85 | $130,714.95 | |
| 11/19/2014 | Matthew M Gosling | VP | Sell | 71,000 | $15.36 | $1,090,560.00 | |
| 3/14/2014 | James Schoeneck | CEO | Sell | 17,000 | $14.54 | $247,180.00 | |
| 3/14/2014 | Matthew Gosling | VP | Sell | 21,875 | $14.74 | $322,437.50 | |
| 12/2/2013 | Michael Md Sweeney | CMO | Sell | 4,270 | $8.40 | $35,868.00 | |
| 12/2/2013 | Thadd Vargas | VP | Sell | 5,296 | $8.40 | $44,486.40 | |
| 5/10/2013 | James A Schoeneck | CEO | Buy | 25,000 | $5.11 | $127,750.00 | |
| 3/6/2013 | Karen A Dawes | Director | Buy | 2,000 | $5.96 | $11,920.00 | |
| 8/14/2012 | Peter D Staple | Director | Buy | 5,000 | $5.01 | $25,050.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Depomed (NASDAQ:DEPO)
Latest Headlines for Depomed (NASDAQ:DEPO)
| Source: |
|
| Date | Headline |
|---|
 | Depomed, Inc. :DEPO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
finance.yahoo.com - September 21 at 5:53 PM |
| Scott+Scott, Attorneys at Law, LLP Reminds Investors of October 17th Lead Plaintiff Deadline in Securities Class Action Against Depomed, Inc. (DEPO)
finance.yahoo.com - September 21 at 5:53 PM |
| EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 21 at 5:53 PM |
 | DEPOMED INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages ... - PR Newswire (press release)
www.prnewswire.com - September 20 at 11:47 PM |
| The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Depomed, Inc. Shareholders and a Lead Plaintiff Deadline of October 17, 2017 (DEPO)
finance.yahoo.com - September 20 at 6:46 PM |
| SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 20 at 6:45 PM |
 | Relative Strength Alert For Depomed
www.thestreet.com - September 19 at 5:48 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 - DEPO
finance.yahoo.com - September 19 at 5:48 PM |
| INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Depomed, Inc. (Nasdaq: DEPO) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - September 19 at 5:48 PM |
| INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 19 at 5:48 PM |
| INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 18 at 5:50 PM |
| INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 18 at 5:50 PM |
 | DEPO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Depomed, Inc. and a Lead Plaintiff Deadline of October 17, 2017
feeds.benzinga.com - September 18 at 12:34 PM |
 | RM LAW Announces Class Action Lawsuit Against Depomed, Inc.
www.streetinsider.com - September 16 at 5:17 PM |
| RM LAW Announces Class Action Lawsuit Against Depomed, Inc. - PR Newswire (press release)
www.prnewswire.com - September 16 at 4:24 AM |
| SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 16 at 4:24 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 – DEPO
finance.yahoo.com - September 15 at 6:20 PM |
 | In the eye of the storm: Drug developers deal with business fallout from opioid crisis - San Francisco Business Times
www.bizjournals.com - September 14 at 11:43 PM |
 | INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Depomed, Inc. Investors ... - Business Wire (press release)
www.businesswire.com - September 14 at 11:43 PM |
| The Klein Law Firm Notifies Investors of Commencement of a Class Action Filed on Behalf of Depomed, Inc. Shareholders and a Lead Plaintiff Deadline of October 17, 2017 (DEPO)
finance.yahoo.com - September 14 at 6:39 PM |
| IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 14 at 6:38 PM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 - DEPO
finance.yahoo.com - September 14 at 12:12 AM |
| IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 14 at 12:12 AM |
| EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Depomed, Inc. – DEPO
feeds.benzinga.com - September 13 at 6:23 PM |
 | Depomed, Inc. (DEPO) Presents at the Morgan Stanley 2017 Global Healthcare Conference (Transcript)
seekingalpha.com - September 13 at 4:43 AM |
| DEPO EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Depomed, Inc. and a Lead Plaintiff Deadline of October 17, 2017
finance.yahoo.com - September 13 at 4:43 AM |
 | Depomed, Inc. (DEPO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 12 at 10:40 PM |
| IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
feeds.benzinga.com - September 12 at 6:13 PM |
| Bragar Eagel & Squire, PC Announces That a Class Action Lawsuit Has Been Filed Against Depomed, Inc. (DEPO) and ... - Business Wire (press release)
www.businesswire.com - September 11 at 11:29 PM |
| ValuEngine Upgrades Depomed, Inc. (DEPO) to Sell
www.americanbankingnews.com - September 11 at 10:54 PM |
| IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
feeds.benzinga.com - September 11 at 7:58 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 - DEPO
finance.yahoo.com - September 11 at 6:27 PM |
| Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Depomed, Inc. (DEPO) and Encourages Investors to Contact the Firm
finance.yahoo.com - September 11 at 6:27 PM |
| Depomed, Inc. (DEPO) Receives Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - September 10 at 9:54 AM |
| IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 9 at 4:15 AM |
| The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Depomed, Inc. Shareholders and a Lead Plaintiff Deadline of October 17, 2017
finance.yahoo.com - September 8 at 6:11 PM |
| EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 7 at 10:57 PM |
| There's only one deadly conspiracy Americans really need to think about
finance.yahoo.com - September 7 at 5:55 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Depomed, Inc. of Class Action Lawsuit and Upcoming Deadline – DEPO
finance.yahoo.com - September 7 at 5:54 PM |
| DEPO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Depomed, Inc. and a Lead Plaintiff Deadline of October 17, 2017
finance.yahoo.com - September 7 at 5:54 PM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of Commencement of a Class Action ... - Business Wire (press release)
www.businesswire.com - September 7 at 3:54 AM |
| SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Depomed, Inc. to Contact Brower Piven Before the Lead Plaintiff ...
www.businesswire.com - September 6 at 5:50 PM |
| SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Depomed, Inc. to Contact Brower Piven Before the Lead Plaintiff ...
www.businesswire.com - September 6 at 5:50 PM |
 | Explosive leaked audio reveals the moment a drug company lied about a patient having cancer to get them opioids
www.businessinsider.com - September 6 at 5:50 PM |
| Explosive leaked audio reveals the moment a drug company lied about a patient having cancer to get them opioids
www.businessinsider.com - September 6 at 5:50 PM |
| SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Depomed, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit
finance.yahoo.com - September 6 at 5:50 PM |
| SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Depomed, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit
finance.yahoo.com - September 6 at 5:50 PM |
| What Does Depomed Inc’s (DEPO) Share Price Indicate?
finance.yahoo.com - September 6 at 5:50 PM |
| What Does Depomed Inc’s (DEPO) Share Price Indicate?
finance.yahoo.com - September 6 at 5:50 PM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017
finance.yahoo.com - September 6 at 5:49 PM |
Depomed (DEPO) Chart for Friday, September, 22, 2017
